Comparative Pharmacology
Head-to-head clinical analysis: LYBALVI versus RISPERDAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYBALVI versus RISPERDAL.
LYBALVI vs RISPERDAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYBALVI is a combination of olanzapine and samidorphan. Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C, dopamine D1-D4, histamine H1, and alpha1-adrenergic receptors. Samidorphan is an opioid receptor antagonist with high affinity for mu-opioid receptors, hypothesized to reduce olanzapine-associated weight gain by blocking opioid receptors in the central nervous system.
Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.
Olanzapine 10 mg / samidorphan 10 mg orally once daily.
2-8 mg orally once daily or divided twice daily; maximum 16 mg/day
None Documented
None Documented
Terminal half-life ~20-30 hours; supports once-daily dosing.
20 hours (parent drug), 23 hours (active metabolite 9-hydroxyrisperidone). Steady state reached in 5-6 days. Extended in elderly and hepatic/renal impairment.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40%; Biliary: minor.
Renal: 70% (30% as unchanged drug, 40% as metabolites), Fecal/Biliary: 14%
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic